Dr. Ilan Goldenberg is a Professor of Medicine and Cardiology at the University of Rochester, New York. He is the Director of the Clinical Cardiovascular Research Center at the University of Rochester from 2018.
Professor Goldenberg has been involved in clinical research with cardiac arrhythmias for over 20 years, as documented by over 600 published papers. He has a substantial record of being the Principal Investigator of large clinical studies and multicenter trial. He is currently the principal investigator on more than 10 research grants from industry and Federal worth over $20 million, including a multicenter randomized clinical trial designed to evaluate the benefit of insertable cardiac monitoring to improve clinical outcomes in heart failure patients.
Professor Goldenberg was the PI of several multicenter clinical trials of device therapy, including the long-term MADIT-CRT trial (Goldenberg et al. NEJM 2014); the first prospective wearable cardioverter defibrillator (WEARIT-II) Registry (Goldenberg et al. Circulation 2015); and the prospective Study of the Wearable Cardioverter Defibrillator in Advanced Heart-Failure Patients (SWIFT) trial (Goldenberg et al. JCE, 2017). Currently he is the PI of the prestigious AHA Strategically Focused Research Network on Arrhythmias and Sudden Cardiac Death on Genomic and Precision Medicine Approaches to Evaluate Sex-Specific Sudden Cardiac Arrest Risk and Resuscitation Outcomes, focusing on sex-specific risk for sudden cardiac death in long-QT syndrome involving genomic studies, clinical trials, and database studies. He currently serves as PI and Co-PI of 4 NIH-funded projects, including serving as the Principal Investigator for the 1R61HL153001-01A1 clinical trial titled “Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation (ICM-REDUCE-AF Trial)”.
Professor Goldenberg also currently serves as the PI of several multicenter clinical trials of device therapy, conducted in the U.S. and in Europe, including the ASSERT-AF trial for early AF detection with the insertable cardiac monitoring for AF detection and the PRIMARY PREVENT VT trial that will evaluate for the first the role of prophylactic VT ablation at the time of ICD implant for primary prevention.
The Clinical Cardiovascular Research Center (CCRC) at the University of Rochester Medical Center, under the Directorship of Professor Goldenberg, is an internationally recognized research enterprise known for its many years of successfully conducting high impact cardiovascular research that has changed the practice of medicine and guideline recommendations in the field of device therapy for the prevention of sudden cardiac death and heart failure. Its innovative, dynamic and cross-functional collaboration with many leading medical centers and research departments throughout the world continues to foster pioneering research that brings forth new treatment paradigms aimed at improving the lives of our patients.